Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology

Ekusheva E.V.

doi:https://doi.org/10.17116/jnevro202112110160

Close metadata

OBJECTIVE

Of an open observational noncomparative clinical study was to study in patients with CCI and tinnitus and/or head the efficacy and tolerability of Sermion in a daily dose of 30 mg for 6 months.

MATERIAL AND METHODS

56 patients (51.1±8.7 years) were clinically and neurologically examined using standard questionnaires to analyze the severity of tinnitus and its impact on daily life and the level of patient distress associated with noise, and to study the quality of life using the SF-36 questionnaire. All patients independently assessed the therapy satisfaction index.

RESULTS AND CONCLUSION

The safety, good tolerance and obvious clinical effect were shown when using the drug Sermion. The best results were obtained with the use of Sermion for 6 months in relation to the severity of tinnitus, the degree of its influence on daily activity, the level of distress and an increase in the quality of life of patients, as well as a significant improvement in well-being and cognitive functions in almost all subjects. It has been shown that after an adequate course of therapy and after 3 months, the therapeutic efficacy of Sermion is preserved, and the patients themselves were more satisfied with this remedy after 6 months of treatment. The data obtained suggest a wider use of Sermion in patients with cerebrovascular diseases and tinnitus and/or head, the use of which allows a safe, effective and pathogenetically reasonable effect on the existing disorders in these patients.

Keywords:

tinnitus

chronic cerebral ischemia

nicergoline

Sermion

Authors:

Ekusheva E.V.

Academy of Postgraduate Education under the Federal State Budgetary Unit «Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»;
Belgorod State National Research University

SPIN RSCI: 8828-0015
Scopus AuthorID: 6507964640
ORCID: 0000-0002-3638-6094

Received:

18.08.2021

Accepted:

29.09.2021

Close metadata

References:

Polikarpov AV, Alexandrova GA, Golubev NA, et al. The general incidence of the adult population of Russia in 2017. Part 4. M. 2018;13. (In Russ.). Aaccess date: 05.01.21. https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god
Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. The Lancet Neurology. 2013;12(5):483. https://doi.org/10.1016/S1474-4422(13)70060-7
Vermeer SE, William T, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. The Lancet Neurology. 2007;6:611-619. https://doi.org/10.1016/S1474-4422(07)70170-9
Moulin S, Cordonnier C. Role of Cerebral Microbleeds for Intracerebral Haemorrhage and Dementia. Current Neurology and Neuroscience Reports. 2019;19(8):51. https://doi.org/10.1007/s11910-019-0969-0
Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathologica. 2011;122(2):171-185. https://doi.org/10.1007/s00401-011-0851-x
Smith EE, O’Donnell M, Dagenais G, Lear SA, Wielgosz A, Sharma M., Poirier P, Stotts G, Black SE, Strother S, Noseworthy MD, Benavente O, Modi J, Goyal M, Batool S, Sanchez K, Hill V, McCreary CR, Frayne R, Islam S, DeJesus J, Rangarajan S, Teo K, Yusuf S, PURE Investigators. Early cerebral small vessel disease and brain volume, cognition, and gait. Annals of Neurology. 2015;77(2):251-261. https://doi.org/10.1002/ana.24320
Filley CM, Fields RD. White matter and cognition: making the connection. The Journal of Neurophysiology. 2016;116(5):2093-2104. https://doi.org/10.1152/jn.00221.2016
Neverovsky DV, Sluchevskaya SF, Parfenov VA. Differential diagnosis of dyscirculatory encephalopathy in outpatient practice. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2013;5(2):38-42. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2411
Preobrazhenskaya IS, Yakhno NN. Vascular cognitive impairment — clinical manifestations, diagnostic approaches and treatment. Nevrologicheskii Zhurnal. 2007;12(5):45-50. (In Russ.). https://elibrary.ru/item.asp?id=9560205
Tunkel DE, Bauer CA, Sun GH, Rosenfeld RM, Chandrasekhar SS, Cunningham ER, Archer SM, Blakley BW, Carter JM, Granieri EC, Henry JA, Hollingsworth D, Khan FA, Mitchell S, Monfared A, Newman CW, Omole FS, Phillips CD, Robinson SK, Taw MB, Tyler RS, Waguespack R, Whamond EJ. Clinical Practice Guideline: tinnitus. Otolaryngology — Head and Neck Surgery. 2014;151(2S):1-40. https://doi.org/10.1177/0194599814545325
Gunenkov AV, Kosyakov SYa. Subjective tympanophonia. The current concepts of therapy. Vestnik Otorinolaringologii. 2014;3:72-75. (In Russ.). https://doi.org/10.17116/otorino201883382
McCormack A, Edmondson-Jones M, Somerset S, Hall D. A systematic review of the reporting of tinnitus prevalence and severity. Hearing Researche. 2016;337:70-79. https://doi.org/10.1016/j.heares.2016.05.009
Gilaeva AR, Safiullina GI, Mosikhin SB. Clinical and diagnostic aspects of tinnitus. Rossijskij Zhurnal Boli. 2019;17(S1):6-7. (In Russ.). https://elibrary.ru/item.asp?id=9560205
Cima RFF, Mazurek B, Haider H, Kikidis D, Lapira A, Norena A, Hoare DJ. A multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment. HNO. 2019;67(suppl 1):10-42. https://doi.org/10.1007/s00106-019-0633-7
McFerran DJ, Stockdale D, Holme R, Large CH and Baguley DM. Why Is There No Cure for Tinnitus? Frontiers in Neuroscience. 2019;13:802. https://doi.org/10.3389/fnins.2019.00802
Instructions for the medical use of the drug Sermion, approved by the Ministry of Health of the Russian Federation N N011253/01. Instructions for the medical use of the drug Sermion, approved by the Ministry of Health of the Russian Federation N N012181/01. (In Russ.).
Im JJ, Jeong HS, Park J-S, Yang YS, Na S-H, Oh JK, Chung YA, Song IU. Changes in regional cerebral perfusion after nicergoline treatment in early Alzheimer’s disease: a pilot study. Dementia and Neurocognitive Disorders. 2017;16(4):104-109. https://doi.org/10.12779/dnd.2017.16.4.104
Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014;4(7):e005090. https://doi.org/10.1136/bmjopen-2014-005090
Winblad B, Carfagna N, Bonura L, Rosssini BM, Wong EHF, Battaglia A. Nicergoline in dementia. A review of its pharmacological properties and therapeutic potential. CNS Drugs. 2000;14(4):267-287. https://doi.org/10.2165/00023210-200014040-00003
Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A. Therapeutic use of nicergoline. Clinical Drug Investigation. 2008;28:533-552. https://doi.org/10.2165/00044011-200828090-00001
Boulu P. Effets du Sermion sur les troubles mn.esiques et les fonctions de la vie de relation. Tempo Medical. 1990;397:24-27.
Felisati G, Battaglia A, Papini MG, Rossini BM, Pignataro O. Nicergoline in balance alterations in adult and elderly patients: a double-blind, placebo-controlled study. Clinical Drug Investigation. 2002;22:731-740. https://doi.org/10.1016/j.archger.2004.04.023
Felisati G, Pignataro O, Girolamo ADi, Bruno E, Alessandrini M, Guidetti G, Monzani D, Beldi AM, Mira E, Benazzo M, Pallestrini E, Caligo G, Casani A, Battaglia A. Nicergoline in the treatment of dizziness in elderly patients. A review. Archives of Gerontology and Geriatrics. 2004;(suppl 9):163-170. https://doi.org/10.1016/j.archger.2004.04.023
Herrmann WM, Stephan K, Gaede K, Apeceche M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dementia and Geriatric Cognitive Disorders. 1997;8(1):9-17. https://doi.org/10.1159/000106595
Saletu B, Garg A, Shoeb A. Safety of nicergoline as an agent for management of cognitive function disorders. BioMed Researche International. 2014;2014:610103. https://doi.org/10.1155/2014/610103
Bès A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, Calvez R, Stehlé B. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. European Journal of Neurology. 1999;6(3):313-322. https://doi.org/10.1046/j.1468-1331.1999.630313.x
Lee S, Na S-H, Chung Y-A, Jeong HS, Song I-U. Efficacy of nicergoline treatment in Parkinson’s disease associated with dementia. Journal of Clinical Neuroscience. 2019;70:136-139. https://doi.org/10.1016/j.jocn.2019.08.048
Takemoto M, Ohta Y, Hishikawa N, Yamashita T, Nomura E, Tsunoda K, Sasaki R, Tadokoro K, Matsumoto N, Omote Y, Abe K. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer’s Disease: The Okayama Depression and Apathy Project (ODAP). Journal of Alzheimer’s Disease. 2020;76(2):769-772. https://doi.org/10.3233/JAD-200247
Akisada T. Effect of nicergoline on vertigo and tinnitus. Practica Otologica Kyoto. 1994;87:845-845. https://doi.org/10.5631/jibirin.87.845
Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. The Archives of OtolaryngologyHead & Neck Surgery. 1996;122(2):143-148. https://doi.org/10.1001/archotol.1996.01890140029007
Wilson PH, Henry J, Bowen M, Haralambous G. Tinnitus reaction questionnaire: psychometric properties of a measure of distress associated with tinnitus. Journal of Speech, Language, and Hearing Researche. 1991;34(1):197-201. https://doi.org/10.1044/jshr.3401.197
Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user`s manual. The Health Institute, New England Medical Center. Boston, Mass. 1994.
Novik AA, Ionova TI. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine. Guidelines for quality of life research in medicine. SPb.: Neva; 2002. (In Russ.).
Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Systematic Reviews. 2001;2001(4):CD003159. https://doi.org/10.1002/14651858.CD003159
Saletu B, Anderer P, Scmlitseh HV. Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dementia and Geriatric Cognitive Disorders. 1997;1(8):12-21. https://doi.org/10.1159/000106666
Saletu B, Griinberger J, Linzmayer L, Anderer P. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. The Journal of Neural Transmission. 1990;2:305-325. https://doi.org/10.1007/BF02252925
Fernández-Blázquez MA, Ávila-Villanueva M, Maestú F, Miguel M. Specific features of subjective cognitive decline predict faster conversion to mild cognitive impairment. Journal of Alzheimer`s Disease. 2016;52(1):271-281. https://doi.org/10.3233/JAD-150956